The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000516381p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
7/04/2026
Date registered
Help: Date registered
24/04/2026
Date last updated
Help: Date last updated
24/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
24/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Dropless cataract surgery with a single subconjunctival triamcinolone injection versus topical steroid: a randomised controlled trial assessing effects on central macular thickness.
Scientific title
Prospective randomized non-inferiority trial evaluating the efficacy of a single subconjunctival triamcinolone acetonide injection compared with topical prednisolone acetate/phenylephrine hydrochloride in reducing central macular thickness change after cataract surgery.
Additional trial identifiers [1] 316958 0
Nil
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Cystoid macular oedema 341401 0
Steroid-induced glaucoma 341402 0
Post operative uveitis 341403 0
Condition category
Condition code
Eye 337468 337468 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention: Subconjunctival triamcinolone acetonide injection

Brief name: Single intraoperative subconjunctival triamcinolone acetonide (TA) 5 mg injection (dropless arm).

Drug details:
International Non-proprietary Name (INN): Triamcinolone acetonide
Dose: 5 mg (0.5 mL of 10 mg/mL solution).
Duration of administration: Single dose only.
Mode of administration: Subconjunctival injection.

Description:
The intervention consists of a single 0.5 mL subconjunctival injection of triamcinolone acetonide (TA) 10 mg/mL (Kenacort A10), delivering 5 mg of TA, administered in the subconjunctival plane at least 6 mm below the limbus. The injection is given immediately after completion of routine phacoemulsification cataract surgery and intraocular lens implantation. Prior to the TA injection, 0.2 mL of 2 % lignocaine is instilled subconjunctivally for local analgesia. No additional topical, intracameral, or intraocular steroids are given to participants in this arm, and Prednefrin Forte eye drops are not prescribed. The injection is performed by a RANZCO-accredited ophthalmologist or ophthalmology registrar within Bayside Health's operating theatres. No further doses are administered during the 12-week study follow-up. The dose, volume, concentration, and injection site are fixed by protocol for all participants.

Strategies to ensure fidelity of the intervention: A pamphlet outlining the correct administration of the intervention medication will be provided to all involved operating theatres to ensure the technique is uniform across all patients randomised to the intervention arm. Additionally, at the 2 week post operative review, the operation report within the patient electronic medical record will be reviewed by a clinician to ensure they recieved the correct dose of the intervention medication.
Intervention code [1] 333692 0
Prevention
Intervention code [2] 333693 0
Treatment: Drugs
Description of the comparator or control
Comparator: Topical prednisolone acetate/phenylephrine hydrochloride eye drops
Brief name: Four-week regimen of Prednefrin Forte eye drops (topical steroid arm).

Drug details:
International Non-proprietary Name (INN): Prednisolone acetate and phenylephrine hydrochloride
Dose: Prednisolone acetate 1% / phenylephrine hydrochloride 0.12% (Prednefrin Forte). One drop instilled four times daily.
Duration of administration: Four weeks.
Mode of administration: Topical eye drops (self-administered).
Description:
The comparator consists of a four-week regimen of Prednefrin Forte eye drops (prednisolone acetate 1%/phenylephrine hydrochloride 0.12%). One drop is instilled four times daily into the operated eye. This regimen is not prescribed to individuals in the intervention group. The drops are self-administered by the participant at home following discharge after routine phacoemulsification cataract surgery and intraocular lens implantation. No additional topical, intracameral, or intraocular steroids are given to participants in this arm, and subconjunctival triamcinolone injection is not administered. The dose, frequency, and duration are fixed by protocol for all participants in this arm. No further doses are administered after the 4-week period during the 12-week study follow-up.

Strategies to ensure fidelity of the comparator: As is standard practice at the institution, all patients assigned to the comparator arm will be eductaed on correct drop instillation technique and the importance of adherence following the operation by either the operating surgeon or registrar. Additionally a pamphlet will be provided outlining how to self-administer the eye drops, as well as the frequency of administration. Adherence to the topical regimen will not be actively enforced, as the study aims to reflect real-world conditions. If patients require a deviation from treatment due to a complication, this will be recorded and reported in any subsequent analysis
Control group
Active

Outcomes
Primary outcome [1] 344982 0
Change in central macular thickness from baseline
Timepoint [1] 344982 0
3 weeks (primary endpoint) and 8 weeks post intervention
Secondary outcome [1] 460032 0
Intra-ocular pressure difference from baseline
Timepoint [1] 460032 0
3 weeks and 8 weeks post intervention
Secondary outcome [2] 460033 0
Presence of cystoid macular oedema
Timepoint [2] 460033 0
3 weeks and 8 weeks following the intervention
Secondary outcome [3] 460036 0
Anterior chamber inflammation
Timepoint [3] 460036 0
3 weeks following intervention
Secondary outcome [4] 460037 0
Best corrected viusal acuity
Timepoint [4] 460037 0
3 week and 8 weeks post intervention
Secondary outcome [5] 460038 0
Eye discomfort
Timepoint [5] 460038 0
3 week and 8 weeks post intervention

Eligibility
Key inclusion criteria
Patients who have a cataractous lens according to the lens opacities grading system III
Postcode is within geographical area of Melbourne
Pt is at least 18 years of age
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Prior history of uveitis, corneal disease that is not dry eye disease or pterygium, endophthalmitis, or history of steroid response (IOP rise with ocular steroid administration)
History of glaucoma requiring >2 pressure lowering agents, or any pressure lowering drops with the exception of a prostaglandin analogue or alpha agonist
Any prior history of significant macular disease which may cause confusion with interpreting OCT or may mimic post operative cystoid macular oedema including advanced macular degeneration, geographic atrophy, chronic serous retinopathy and epiretinal membranes > stage 2 as per Govetto et al.’s grading system (Govetto et al., 2017)
Any prior history of retinal disease which may increase the risk of post-operative cystoid macular oedema including history of cystoid macular oedema in either eye, current or previous diabetic macular oedema anywhere on 3D macular OCT scan, moderate or severe non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, neovascular age related macular degeneration or retinal vein occlusion .
Significant/moderate drusen impacting OCT reading
Dense or brunescent cataract which prevents a pre-operative OCT being acquired
Non-elective surgery
Any previous intra-ocular surgery to the study eye
Patients on systemic anti-inflammatory therapy (not including NSAID or paracetamol use)
Patients who develop significant intra-operative complications including posterior capsule rupture
Currently pregnant or planning to conceive in the near future (female patients)

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation through REDCap
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Stata Software (version 18) is used to generate a random allocation sequence to enroll eligible patients into the trial. Random permuted blocks of varying sizes (2,4,6,8) will be used to conceal allocations. Randomisation will be stratified by diabetes and ERM status to ensure balanced allocation between treatment groups
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3 / Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The standard deviation of change in central macular thickness from baseline to follow-up at between 1 to 2 months has been estimated as 26 µm based on pilot data collected by the investigators from patients who underwent cataract surgery and were assessed using the Zeiss Cirrus OCT. Given the intersession repeatability published for the Zeiss Cirrus OCT, and the author’s clinical experience, a non-inferiority margin of 10 µm is considered to be significant (Wolf-Schnurrbusch et al., 2009). A total sample size of 232 (116 per arm) is required to establish non-inferiority with 90% power at the 5% level of significance. Non-inferiority will be demonstrated if the lower limit of the 95% confidence interval for the difference between treatment arms lies above -10 µm. Accounting for approximately 20% attrition, a total of 300 patients (150 per group) will be enrolled.

The mean change in central macular thickness from baseline to follow-up at 3 weeks will be estimated in each treatment group. Difference between groups and the corresponding 95% confidence intervals (95% CI) will be determined. Non-inferiority will be established if the lower limit of the 95% CI lies above the pre-specified non-inferiority margin of -10.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 29368 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 45686 0
3004 - Melbourne

Funding & Sponsors
Funding source category [1] 321554 0
Hospital
Name [1] 321554 0
Ophthalmology Research Fund. Alfred Hospital.
Country [1] 321554 0
Australia
Primary sponsor type
Government body
Name
Bayside Health
Address
Country
Australia
Secondary sponsor category [1] 324343 0
None
Name [1] 324343 0
Address [1] 324343 0
Country [1] 324343 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320088 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 320088 0
Ethics committee country [1] 320088 0
Australia
Date submitted for ethics approval [1] 320088 0
08/04/2026
Approval date [1] 320088 0
Ethics approval number [1] 320088 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149390 0
Dr David van der Straaten
Address 149390 0
Alfred Hospital, 55 Commercial Road, Melbourne 3004, Victoria
Country 149390 0
Australia
Phone 149390 0
+61 425701051
Fax 149390 0
Email 149390 0
Contact person for public queries
Name 149391 0
David van der Straaten
Address 149391 0
Alfred Hospital, 55 Commercial Road, Melbourne 3004, Victoria
Country 149391 0
Australia
Phone 149391 0
+61 425701051
Fax 149391 0
Email 149391 0
Contact person for scientific queries
Name 149392 0
David van der Straaten
Address 149392 0
Alfred Hospital, 55 Commercial Road, Melbourne 3004, Victoria
Country 149392 0
Australia
Phone 149392 0
+61 425701051
Fax 149392 0
Email 149392 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.